Analysis group,Analysis number,Analysis name,Subgroup,Subgroup number,Applicability,Study,Study year,GIV Mean,GIV SE,Experimental mean,Experimental SD,Experimental cases,Experimental N,Control mean,Control SD,Control cases,Control N,O-E,Variance,Weight,Mean,CI start,CI end,Footnotes
1,1,Depression response (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,1,10,0.0,0.0,0,11,0.0,0.0,10.948405,3.272727,0.14828,72.233205,
1,1,Depression response (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,1,92,0.0,0.0,1,46,0.0,0.0,13.870179,0.5,0.031992,7.814425,
1,1,Depression response (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,5,54,0.0,0.0,5,54,0.0,0.0,75.181416,1.0,0.307031,3.257004,
1,1,Depression response (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,2,10,0.0,0.0,1,11,0.0,0.0,7.242224,2.2,0.233623,20.717115,
1,1,Depression response (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,10,92,0.0,0.0,3,46,0.0,0.0,23.658963,1.666667,0.481964,5.76346,
1,1,Depression response (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,11,54,0.0,0.0,12,54,0.0,0.0,69.098813,0.916667,0.443523,1.894554,
1,1,Depression response (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,3,10,0.0,0.0,1,11,0.0,0.0,4.667812,3.3,0.406175,26.81108,
1,1,Depression response (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,20,92,0.0,0.0,8,46,0.0,0.0,37.45047,1.25,0.596638,2.61884,
1,1,Depression response (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,15,54,0.0,0.0,16,54,0.0,0.0,57.881718,0.9375,0.517139,1.699555,
1,1,Depression response (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,4,10,0.0,0.0,2,11,0.0,0.0,6.954159,2.2,0.508111,9.525469,
1,1,Depression response (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,23,92,0.0,0.0,13,46,0.0,0.0,44.286251,0.884615,0.494931,1.581117,
1,1,Depression response (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,15,54,0.0,0.0,19,54,0.0,0.0,47.26416,0.789474,0.44999,1.385073,
1,1,Depression response (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,NCT03228394,2017,0.0,0.0,0.0,0.0,0,30,0.0,0.0,1,28,0.0,0.0,1.49543,0.311828,0.013226,7.35219,
1,1,Depression response (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,7,10,0.0,0.0,3,11,0.0,0.0,11.092246,2.566667,0.901007,7.311576,
1,1,Depression response (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,40,92,0.0,0.0,16,46,0.0,0.0,36.978892,1.25,0.789738,1.978505,
1,1,Depression response (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,26,54,0.0,0.0,24,54,0.0,0.0,41.999072,1.083333,0.721217,1.627264,
1,1,Depression response (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,NCT03228394,2017,0.0,0.0,0.0,0.0,4,30,0.0,0.0,7,28,0.0,0.0,9.92979,0.533333,0.174835,1.626929,
1,1,Depression response (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,8,10,0.0,0.0,4,11,0.0,0.0,11.302112,2.2,0.948872,5.100792,
1,1,Depression response (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,51,92,0.0,0.0,18,46,0.0,0.0,40.303625,1.416667,0.94553,2.122561,
1,1,Depression response (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,30,54,0.0,0.0,27,54,0.0,0.0,48.394263,1.111111,0.776873,1.58915,
1,1,Depression response (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,8,10,0.0,0.0,4,11,0.0,0.0,8.081384,2.2,0.948872,5.100792,
1,1,Depression response (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,57,92,0.0,0.0,28,46,0.0,0.0,43.533319,1.017857,0.768015,1.348975,
1,1,Depression response (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,34,54,0.0,0.0,26,54,0.0,0.0,34.186141,1.307692,0.926899,1.844925,
1,1,Depression response (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,NCT03228394,2017,0.0,0.33806170189140666,0.0,0.0,12,30,0.0,0.0,12,28,0.0,0.11428571428571431,14.199156,0.933333,0.505926,1.721815,
1,1,Depression response (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,7,10,0.0,0.0,4,11,0.0,0.0,4.800026,1.925,0.797834,4.644608,
1,1,Depression response (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,63,92,0.0,0.0,24,46,0.0,0.0,38.881572,1.3125,0.96316,1.788546,
1,1,Depression response (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,38,54,0.0,0.0,31,54,0.0,0.0,45.009249,1.225806,0.9194,1.634329,
1,1,Depression response (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,NCT03228394,2017,0.0,0.0,0.0,0.0,14,30,0.0,0.0,12,28,0.0,0.0,11.309153,1.088889,0.613447,1.932813,
1,1,Depression response (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,8,10,0.0,0.0,3,11,0.0,0.0,3.632043,2.933333,1.064581,8.082467,
1,1,Depression response (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,62,92,0.0,0.0,24,46,0.0,0.0,34.698871,1.291667,0.946371,1.762949,
1,1,Depression response (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,38,54,0.0,0.0,33,54,0.0,0.0,43.261309,1.151515,0.8753,1.514895,
1,1,Depression response (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,NCT03228394,2017,0.0,0.0,0.0,0.0,19,30,0.0,0.0,15,28,0.0,0.0,18.407777,1.182222,0.761883,1.834467,
1,1,Depression response (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,8,10,0.0,0.0,2,11,0.0,0.0,8.366515,4.4,1.209577,16.005591,
1,1,Depression response (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,48,92,0.0,0.0,21,46,0.0,0.0,44.176464,1.142857,0.788567,1.656323,
1,1,Depression response (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,34,54,0.0,0.0,27,54,0.0,0.0,47.457021,1.259259,0.899778,1.762362,
1,1,Depression response (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.5341173890460648,0.0,0.0,7,10,0.0,0.0,3,11,0.0,0.28528138528138525,15.903437,2.566667,0.901007,7.311576,
1,1,Depression response (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.16650107779415904,0.0,0.0,61,92,0.0,0.0,22,46,0.0,0.027722608906616604,40.127171,1.386364,0.991576,1.938333,
1,1,Depression response (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.12062447740929098,0.0,0.0,36,54,0.0,0.0,42,54,0.0,0.01455026455026455,43.969391,0.857143,0.676671,1.085748,
1,2,Depression remission (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,1.5787413475374117,0.0,0.0,0,10,0.0,0.0,0,11,0.0,2.492424242424242,,,,,
1,2,Depression remission (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,1,54,0.0,0.0,1,54,0.0,0.0,100.0,1.0,0.064183,15.580542,
1,2,Depression remission (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,1.5787413475374117,0.0,0.0,1,10,0.0,0.0,0,11,0.0,2.492424242424242,24.885435,3.272727,0.14828,72.233205,
1,2,Depression remission (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,2,54,0.0,0.0,4,54,0.0,0.0,75.114565,0.5,0.095552,2.616376,
1,2,Depression remission (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,1.1441551070947107,0.0,0.0,2,10,0.0,0.0,0,11,0.0,1.309090909090909,25.937599,5.454545,0.29299,101.546242,
1,2,Depression remission (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,1.5095441047731328,0.0,0.0,0,92,0.0,0.0,2,46,0.0,2.278723404255319,24.987188,0.101075,0.004952,2.062965,
1,2,Depression remission (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,6,54,0.0,0.0,3,54,0.0,0.0,49.075213,2.0,0.527061,7.589257,
1,2,Depression remission (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.8015137194235931,0.0,0.0,3,10,0.0,0.0,0,11,0.0,0.6424242424242423,14.945467,7.636364,0.442602,131.752673,
1,2,Depression remission (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,2,92,0.0,0.0,2,46,0.0,0.0,28.680295,0.5,0.072738,3.43699,
1,2,Depression remission (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,7,54,0.0,0.0,4,54,0.0,0.0,56.374238,1.75,0.543614,5.633592,
1,2,Depression remission (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,NCT03228394,2017,0.0,0.0,0.0,0.0,0,30,0.0,0.0,0,28,0.0,0.0,,,,,
1,2,Depression remission (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.5559594491425693,0.0,0.0,6,10,0.0,0.0,1,11,0.0,0.3090909090909091,8.444195,6.6,0.952189,45.747207,
1,2,Depression remission (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,13,92,0.0,0.0,3,46,0.0,0.0,21.346052,2.166667,0.649685,7.225724,
1,2,Depression remission (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,15,54,0.0,0.0,12,54,0.0,0.0,65.913027,1.25,0.646877,2.415453,
1,2,Depression remission (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,NCT03228394,2017,0.0,0.0,0.0,0.0,1,30,0.0,0.0,1,28,0.0,0.0,4.296725,0.933333,0.061266,14.218556,
1,2,Depression remission (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.5090097337879788,0.0,0.0,5,10,0.0,0.0,1,11,0.0,0.25909090909090904,6.044247,5.5,0.767893,39.393501,
1,2,Depression remission (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,18,92,0.0,0.0,6,46,0.0,0.0,32.166455,1.5,0.638908,3.521631,
1,2,Depression remission (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,17,54,0.0,0.0,13,54,0.0,0.0,61.789298,1.307692,0.706439,2.420676,
1,2,Depression remission (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.44938630591958617,0.0,0.0,7,10,0.0,0.0,2,11,0.0,0.2019480519480519,9.582083,3.85,1.030915,14.378007,
1,2,Depression remission (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,19,92,0.0,0.0,7,46,0.0,0.0,26.58769,1.357143,0.61531,2.993346,
1,2,Depression remission (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,22,54,0.0,0.0,13,54,0.0,0.0,50.744949,1.692308,0.95459,3.000142,
1,2,Depression remission (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,NCT03228394,2017,0.0,0.0,0.0,0.0,5,30,0.0,0.0,5,28,0.0,0.0,13.085277,0.933333,0.302241,2.882172,
1,2,Depression remission (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.44938630591958617,0.0,0.0,7,10,0.0,0.0,1,11,0.0,0.2019480519480519,6.437063,7.7,1.137606,52.118218,
1,2,Depression remission (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,31,92,0.0,0.0,7,46,0.0,0.0,27.478584,2.214286,1.056586,4.640476,
1,2,Depression remission (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.2126523629755663,0.0,0.0,30,54,0.0,0.0,20,54,0.0,0.045221027479092,44.938598,1.5,0.983879,2.286866,
1,2,Depression remission (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,NCT03228394,2017,0.0,0.0,0.0,0.0,7,30,0.0,0.0,7,28,0.0,0.0,21.145756,0.933333,0.374821,2.324072,
1,2,Depression remission (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.5341173890460648,0.0,0.0,7,10,0.0,0.0,2,11,0.0,0.28528138528138525,6.041684,3.85,1.030915,14.378007,
1,2,Depression remission (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.3545767021127579,0.0,0.0,31,92,0.0,0.0,8,46,0.0,0.12572463768115943,21.905664,1.9375,0.969882,3.870477,
1,2,Depression remission (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,29,54,0.0,0.0,18,54,0.0,0.0,51.51814,1.611111,1.026034,2.529817,
1,2,Depression remission (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,NCT03228394,2017,0.0,0.0,0.0,0.0,11,30,0.0,0.0,9,28,0.0,0.0,20.534513,1.140741,0.558204,2.331208,
1,2,Depression remission (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.6722708174151634,0.0,0.0,7,10,0.0,0.0,0,11,0.0,0.4519480519480519,8.959916,16.363636,1.053111,254.264415,
1,2,Depression remission (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,20,92,0.0,0.0,13,46,0.0,0.0,43.708141,0.769231,0.421354,1.40432,
1,2,Depression remission (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,28,54,0.0,0.0,17,54,0.0,0.0,47.331943,1.647059,1.02943,2.635248,
1,2,Depression remission (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.5341173890460648,0.0,0.0,7,10,0.0,0.0,2,11,0.0,0.28528138528138525,18.014955,3.85,1.030915,14.378007,
1,2,Depression remission (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.2739630673436226,0.0,0.0,31,92,0.0,0.0,13,46,0.0,0.07505576226832629,38.435902,1.192308,0.69318,2.050834,
1,2,Depression remission (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.1739274206157614,0.0,0.0,23,54,0.0,0.0,32,54,0.0,0.03025074764205199,43.549142,0.71875,0.491274,1.051555,
1,3,Adverse events (mother),Any adverse event,1,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.4290581651605166,0.0,0.0,4,10,0.0,0.0,8,11,0.0,0.1840909090909091,14.352156,0.55,0.237218,1.275198,
1,3,Adverse events (mother),Any adverse event,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.18899579409633646,0.0,0.0,41,92,0.0,0.0,22,46,0.0,0.03571941018610481,35.321855,0.931818,0.638378,1.360143,
1,3,Adverse events (mother),Any adverse event,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.21042866634526358,0.0,0.0,25,54,0.0,0.0,24,54,0.0,0.044280223619846265,32.901626,1.041667,0.688504,1.575982,
1,3,Adverse events (mother),Any adverse event,1,SUBGROUP_AND_OVERALL,NCT03228394,2017,0.0,0.0,0.0,0.0,15,30,0.0,0.0,7,28,0.0,0.0,17.424363,2.0,0.959397,4.169286,
1,3,Adverse events (mother),Severe adverse event,2,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,1.5763402186230246,0.0,0.0,0,10,0.0,0.0,1,11,0.0,2.484848484848485,27.399481,0.363636,0.016476,8.025912,
1,3,Adverse events (mother),Severe adverse event,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,1.626132419977952,0.0,0.0,1,92,0.0,0.0,0,46,0.0,2.6443066473033507,25.920505,1.516129,0.062966,36.506448,
1,3,Adverse events (mother),Severe adverse event,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,1.209385611355278,0.0,0.0,2,54,0.0,0.0,1,54,0.0,1.4626135569531795,46.680014,2.0,0.186843,21.408382,
1,3,Adverse events (mother),Serious adverse event,3,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,0,10,0.0,0.0,0,11,0.0,0.0,,,,,
1,3,Adverse events (mother),Serious adverse event,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,1.6227096800621332,0.0,0.0,1,92,0.0,0.0,0,46,0.0,2.6331867057673506,49.958838,1.516129,0.062966,36.506448,
1,3,Adverse events (mother),Serious adverse event,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,1.6217170930733664,0.0,0.0,1,54,0.0,0.0,0,54,0.0,2.62996632996633,50.041162,3.0,0.124918,72.0473,
1,3,Adverse events (mother),Serious adverse event,3,SUBGROUP_AND_OVERALL,NCT03228394,2017,0.0,0.0,0.0,0.0,0,30,0.0,0.0,0,28,0.0,0.0,,,,,
1,4,Depression severity according to HAMD (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-2.2,2.3,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,4.234277,-2.2,-6.707917,2.307917,
1,4,Depression severity according to HAMD (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.1,1.0,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.0,22.399326,0.1,-1.859964,2.059964,Brexanolone dose 60 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.2,0.9,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.81,27.653488,0.2,-1.563968,1.963968,Brexanolone dose 90 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-0.6,0.7,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,45.712909,-0.6,-1.971975,0.771975,
1,4,Depression severity according to HAMD (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-3.5,2.9,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,4.335898,-3.5,-9.183896,2.183896,
1,4,Depression severity according to HAMD (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-0.3,1.2,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.44,25.32285,-0.3,-2.651957,2.051957,Brexanolone dose 90 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-2.1,1.2,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.44,25.32285,-2.1,-4.451957,0.251957,Brexanolone dose 60 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-0.8,0.9,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,45.018401,-0.8,-2.563968,0.963968,
1,4,Depression severity according to HAMD (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-4.6,3.1,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,4.549015,-4.6,-10.675888,1.475888,
1,4,Depression severity according to HAMD (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-2.0,1.3,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.44,25.867476,-2.0,-4.547953,0.547953,Brexanolone dose 60 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-0.4,1.3,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.44,25.867476,-0.4,-2.947953,2.147953,Brexanolone dose 90 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-1.0,1.0,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,43.716034,-1.0,-2.959964,0.959964,
1,4,Depression severity according to HAMD (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-6.0,3.7,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,3.693649,-6.0,-13.251867,1.251867,
1,4,Depression severity according to HAMD (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-1.3,1.4,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.9599999999999997,20.667686,-1.3,-4.04395,1.44395,Brexanolone dose 60 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.7,1.4,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.9599999999999997,20.667686,0.7,-2.04395,3.44395,Brexanolone dose 90 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-1.1,1.0,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.0,33.12657,-1.1,-3.059964,0.859964,
1,4,Depression severity according to HAMD (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,NCT03228394,2017,1.17,1.35,0.0,0.0,0,30,0.0,0.0,0,28,0.0,1.8140776531290004,21.844409,1.17,-1.475951,3.815951,
1,4,Depression severity according to HAMD (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-11.3,3.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,8.332489,-11.3,-18.35587,-4.24413,
1,4,Depression severity according to HAMD (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-4.3,1.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,22.405641,-4.3,-7.435942,-1.164058,Brexanolone dose 60 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-2.3,1.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,22.405641,-2.3,-5.435942,0.835942,Brexanolone dose 90 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-1.6,1.1,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,28.697167,-1.6,-3.75596,0.55596,
1,4,Depression severity according to HAMD (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,NCT03228394,2017,-0.43,2.0,0.0,0.0,0,30,0.0,0.0,0,28,0.0,4.009285382400001,18.159062,-0.43,-4.349928,3.489928,
1,4,Depression severity according to HAMD (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-12.0,4.0,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,10.370319,-12.0,-19.839856,-4.160144,
1,4,Depression severity according to HAMD (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-5.1,1.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,27.962166,-5.1,-8.235942,-1.964058,Brexanolone dose 60 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-1.4,1.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,27.962166,-1.4,-4.535942,1.735942,Brexanolone dose 90 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-1.9,1.1,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,33.705348,-1.9,-4.05596,0.25596,
1,4,Depression severity according to HAMD (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-12.7,4.0,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,6.477911,-12.7,-20.539856,-4.860144,
1,4,Depression severity according to HAMD (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-4.5,1.7,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,22.935928,-4.5,-7.831939,-1.168061,Brexanolone dose 60 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-3.3,1.7,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,22.935928,-3.3,-6.631939,0.031939,Brexanolone dose 90 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-2.4,1.2,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,31.899806,-2.4,-4.751957,-0.048043,
1,4,Depression severity according to HAMD (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,NCT03228394,2017,-2.52,2.29,0.0,0.0,0,30,0.0,0.0,0,28,0.0,5.263858376099999,15.750427,-2.52,-7.008318,1.968318,
1,4,Depression severity according to HAMD (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-12.2,4.1,0.0,0.0,0,0,0.0,0.0,0,0,0.0,16.81,7.120703,-12.2,-20.235852,-4.164148,
1,4,Depression severity according to HAMD (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-5.5,1.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,2.5600000000000005,22.886049,-5.5,-8.635942,-2.364058,Brexanolone dose 60 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-3.7,1.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,2.5600000000000005,22.886049,-3.7,-6.835942,-0.564058,Brexanolone dose 90 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-2.5,1.0,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,30.207679,-2.5,-4.459964,-0.540036,
1,4,Depression severity according to HAMD (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,NCT03228394,2017,-0.13,2.2,0.0,0.0,0,30,0.0,0.0,0,28,0.0,4.746498393316,16.899521,-0.13,-4.441921,4.181921,
1,4,Depression severity according to HAMD (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-12.7,4.3,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,6.64161,-12.7,-21.127845,-4.272155,
1,4,Depression severity according to HAMD (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-5.0,1.7,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,23.088358,-5.0,-8.331939,-1.668061,Brexanolone dose 60 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-2.5,1.7,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,23.088358,-2.5,-5.831939,0.831939,Brexanolone dose 90 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-3.5,1.1,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,31.484721,-3.5,-5.65596,-1.34404,
1,4,Depression severity according to HAMD (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,NCT03228394,2017,0.23,2.42,0.0,0.0,0,30,0.0,0.0,0,28,0.0,5.844673715776,15.696952,0.23,-4.513113,4.973113,
1,4,Depression severity according to HAMD (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-12.9,3.9,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,11.369997,-12.9,-20.54386,-5.25614,
1,4,Depression severity according to HAMD (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-1.6,1.8,0.0,0.0,0,0,0.0,0.0,0,0,0.0,3.24,27.842025,-1.6,-5.127935,1.927935,Brexanolone dose 90 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-4.1,1.8,0.0,0.0,0,0,0.0,0.0,0,0,0.0,3.24,27.842025,-4.1,-7.627935,-0.572065,Brexanolone dose 60 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-3.2,1.4,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,32.945954,-3.2,-5.94395,-0.45605,
1,4,Depression severity according to HAMD (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-11.9,4.1,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,15.350735,-11.9,-19.935852,-3.864148,
1,4,Depression severity according to HAMD (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-3.8,1.9,0.0,0.0,0,0,0.0,0.0,0,0,0.0,3.61,27.08675,-3.8,-7.523932,-0.076068,Brexanolone dose 90 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-5.6,1.9,0.0,0.0,0,0,0.0,0.0,0,0,0.0,3.61,27.08675,-5.6,-9.323932,-1.876068,Brexanolone dose 60 ug/kg/hour
1,4,Depression severity according to HAMD (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.5,1.3,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.6900000000000002,30.475764,0.5,-2.047953,3.047953,
1,5,Treatment acceptability (measured by dropouts),,,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,1,10,0.0,0.0,0,11,0.0,0.0,6.962061,3.272727,0.14828,72.233205,
1,5,Treatment acceptability (measured by dropouts),,,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,21,92,0.0,0.0,4,46,0.0,0.0,65.478231,2.625,0.957057,7.199804,
1,5,Treatment acceptability (measured by dropouts),,,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,6,54,0.0,0.0,2,54,0.0,0.0,27.559708,3.0,0.633431,14.208326,
2,1,Depression response (early phase),Day 3,1,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,0.23839632302702748,0.0,0.0,30,77,0.0,0.0,20,76,0.0,0.05683280683280684,63.93607,1.480519,0.926525,2.365764,
2,1,Depression response (early phase),Day 3,1,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.3180788007641378,0.0,0.0,26,98,0.0,0.0,12,98,0.0,0.10117412349555206,36.06393,2.166667,1.160803,4.044134,
2,1,Depression response (early phase),Day 8,2,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,0.15559777333821304,0.0,0.0,49,77,0.0,0.0,33,76,0.0,0.024210667067809916,60.340258,1.465565,1.077931,1.992596,
2,1,Depression response (early phase),Day 8,2,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.20545769634944505,0.0,0.0,47,98,0.0,0.0,24,98,0.0,0.04221286498922077,39.659742,1.958333,1.307177,2.933856,
2,1,Depression response (early phase),Day 15,3,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,0.14406147984708187,0.0,0.0,53,77,0.0,0.0,35,76,0.0,0.02075370997573117,55.935509,1.49462,1.122841,1.989497,
2,1,Depression response (early phase),Day 15,3,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.16441164750231152,0.0,0.0,53,98,0.0,0.0,35,98,0.0,0.02703118983442434,44.064491,1.514286,1.097136,2.090043,
2,1,Depression response (early phase),Day 21,4,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,0.1287343206248498,0.0,0.0,53,77,0.0,0.0,41,76,0.0,0.016572525306741626,62.202796,1.275895,0.987331,1.648797,
2,1,Depression response (early phase),Day 21,4,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.16223179148271516,0.0,0.0,50,98,0.0,0.0,35,98,0.0,0.026319154167691174,37.797204,1.428571,1.028144,1.984951,
2,1,Depression response (early phase),Day 28,5,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.16563808254672566,0.0,0.0,48,98,0.0,0.0,35,98,0.0,0.027435974389755903,100.0,1.371429,0.982262,1.914781,
2,2,Depression response (acute phase),,,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,0.12784004541864974,0.0,0.0,55,77,0.0,0.0,39,76,0.0,0.01634307721264243,53.294774,1.391941,1.072622,1.806323,
2,2,Depression response (acute phase),,,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.1378445216559071,0.0,0.0,52,98,0.0,0.0,46,98,0.0,0.01900111215054584,46.705226,1.130435,0.853471,1.497278,
2,3,Depression remission (early phase),Day 3,1,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,0.5430727805074058,0.0,0.0,14,77,0.0,0.0,4,76,0.0,0.2949280449280449,50.775842,3.454545,1.190825,10.021527,
2,3,Depression remission (early phase),Day 3,1,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.5517057655133579,0.0,0.0,8,98,0.0,0.0,5,98,0.0,0.30437925170068025,49.224158,1.6,0.542429,4.719508,
2,3,Depression remission (early phase),Day 8,2,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,0.29426979388770363,0.0,0.0,24,77,0.0,0.0,14,76,0.0,0.08659471159471158,59.796363,1.692022,0.949313,3.015802,
2,3,Depression remission (early phase),Day 8,2,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.35916879443895017,0.0,0.0,17,98,0.0,0.0,11,98,0.0,0.12900222289872884,40.203637,1.545455,0.763747,3.127252,
2,3,Depression remission (early phase),Day 15,3,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,0.2498818052415896,0.0,0.0,33,77,0.0,0.0,17,76,0.0,0.06244091659079572,57.798455,1.915966,1.171572,3.133334,
2,3,Depression remission (early phase),Day 15,3,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.29214974571767555,0.0,0.0,25,98,0.0,0.0,15,98,0.0,0.08535147392290249,42.201545,1.666667,0.937244,2.963773,
2,3,Depression remission (early phase),Day 21,4,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,0.23063275788833068,0.0,0.0,31,77,0.0,0.0,21,76,0.0,0.053191469011177356,59.339242,1.457019,0.925028,2.294962,
2,3,Depression remission (early phase),Day 21,4,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.2767151152503732,0.0,0.0,25,98,0.0,0.0,17,98,0.0,0.0765712550080273,40.660758,1.470588,0.849437,2.545956,
2,3,Depression remission (early phase),Day 28,5,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.2578618834696832,0.0,0.0,26,98,0.0,0.0,20,98,0.0,0.06649275094653247,100.0,1.3,0.779633,2.167687,
2,4,Depression remission (acute phase),,,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,0.21396333015232272,0.0,0.0,39,77,0.0,0.0,21,76,0.0,0.04578030664987185,49.735261,1.833024,1.19786,2.804983,
2,4,Depression remission (acute phase),,,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.2122692618162626,0.0,0.0,37,98,0.0,0.0,25,98,0.0,0.04505823951202104,50.264739,1.48,0.969338,2.259686,
2,5,Adverse events (mother),Any adverse events,1,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,0.14459163908873077,0.0,0.0,47,77,0.0,0.0,38,76,0.0,0.02090674209436577,39.846701,1.220779,0.916176,1.626654,
2,5,Adverse events (mother),Any adverse events,1,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.0,0.0,0.0,65,98,0.0,0.0,52,98,0.0,0.0,60.153299,1.25,0.989582,1.578949,
2,5,Adverse events (mother),Severe adverse events,2,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,0.7999881396262493,0.0,0.0,3,77,0.0,0.0,3,76,0.0,0.6399810235426673,67.210691,0.987013,0.205629,4.737635,
2,5,Adverse events (mother),Severe adverse events,2,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.0,0.0,0.0,3,98,0.0,0.0,1,98,0.0,0.0,32.789309,3.0,0.317533,28.343473,
2,5,Adverse events (mother),Serious adverse events,3,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,1.404747079326382,0.0,0.0,1,77,0.0,0.0,1,76,0.0,1.9733143568760008,54.662095,0.987013,0.062869,15.495642,
2,5,Adverse events (mother),Serious adverse events,3,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.0,0.0,0.0,2,98,0.0,0.0,0,98,0.0,0.0,45.337905,5.0,0.24314,102.821528,
2,5,Adverse events (mother),Deaths,4,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,0.0,0.0,0.0,0,77,0.0,0.0,0,76,0.0,0.0,,,,,
2,5,Adverse events (mother),Deaths,4,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,0.0,0.0,0.0,0,98,0.0,0.0,0,98,0.0,0.0,,,,,
2,6,Depression severity (early phase),Day 3,1,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,-2.7,1.19,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,42.352941,-2.7,-5.032357,-0.367643,
2,6,Depression severity (early phase),Day 3,1,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,-3.4,1.02,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.0283197117210001,57.647059,-3.4,-5.399163,-1.400837,
2,6,Depression severity (early phase),Day 8,2,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,-3.4,1.31,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,40.017476,-3.4,-5.967553,-0.832447,
2,6,Depression severity (early phase),Day 8,2,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,-3.7,1.07,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,59.982524,-3.7,-5.797161,-1.602839,
2,6,Depression severity (early phase),Day 15,3,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,-4.2,1.37,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,42.174502,-4.2,-6.885151,-1.514849,
2,6,Depression severity (early phase),Day 15,3,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,-4.0,1.17,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.3456,57.825498,-4.0,-6.293158,-1.706842,
2,6,Depression severity (early phase),Day 21,4,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,-3.1,1.44,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,41.785514,-3.1,-5.922348,-0.277652,
2,6,Depression severity (early phase),Day 21,4,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,-2.5,1.22,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,58.214486,-2.5,-4.891156,-0.108844,
2,6,Depression severity (early phase),Day 28,5,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,-2.9,1.25,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,100.0,-2.9,-5.349955,-0.450045,
2,7,Depression severity (acute phase),,,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,-4.1,1.34,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.7956000000000003,47.711124,-4.1,-6.726352,-1.473648,
2,7,Depression severity (acute phase),,,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,-3.5,1.28,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.6384,52.288876,-3.5,-6.008754,-0.991246,
2,8,Treatment acceptability,,,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,0.0,1.482030599014304,0.0,0.0,4,77,0.0,0.0,7,76,0.0,2.1964146964146964,28.071079,0.564007,0.172117,1.848183,
2,8,Treatment acceptability,,,SUBGROUP_AND_OVERALL,Deligiannidis 2023,2023,0.0,1.4313502356304553,0.0,0.0,14,98,0.0,0.0,12,98,0.0,2.0487634970393596,71.928921,1.166667,0.568781,2.393033,
2,9," Barkin Index of Maternal Functioning (early phase)",Day 3,1,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,2.2,1.73,0.0,0.0,0,0,0.0,0.0,0,0,0.0,2.9929,100.0,2.2,-1.190738,5.590738,
2,9," Barkin Index of Maternal Functioning (early phase)",Day 8,2,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,1.1,2.19,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.7161000000000002,100.0,1.1,-3.192321,5.392321,
2,9," Barkin Index of Maternal Functioning (early phase)",Day 15,3,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,4.7,2.78,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.8769000000000002,100.0,4.7,-0.7487,10.1487,
2,9," Barkin Index of Maternal Functioning (early phase)",Day 21,4,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,3.6,2.8,0.0,0.0,0,0,0.0,0.0,0,0,0.0,2.0736,100.0,3.6,-1.887899,9.087899,
2,10," Barkin Index of Maternal Functioning (acute phase)",,,SUBGROUP_AND_OVERALL,Deligiannidis 2021,2021,7.2,2.95,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,100.0,7.2,1.418106,12.981894,
3,1,Depression response (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,1,10,0.0,0.0,0,11,0.0,0.0,10.948405,3.272727,0.14828,72.233205,
3,1,Depression response (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,1,92,0.0,0.0,1,46,0.0,0.0,13.870179,0.5,0.031992,7.814425,
3,1,Depression response (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,5,54,0.0,0.0,5,54,0.0,0.0,75.181416,1.0,0.307031,3.257004,
3,1,Depression response (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,2,10,0.0,0.0,1,11,0.0,0.0,7.242224,2.2,0.233623,20.717115,
3,1,Depression response (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,10,92,0.0,0.0,3,46,0.0,0.0,23.658963,1.666667,0.481964,5.76346,
3,1,Depression response (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,11,54,0.0,0.0,12,54,0.0,0.0,69.098813,0.916667,0.443523,1.894554,
3,1,Depression response (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,3,10,0.0,0.0,1,11,0.0,0.0,4.667812,3.3,0.406175,26.81108,
3,1,Depression response (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,20,92,0.0,0.0,8,46,0.0,0.0,37.45047,1.25,0.596638,2.61884,
3,1,Depression response (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,15,54,0.0,0.0,16,54,0.0,0.0,57.881718,0.9375,0.517139,1.699555,
3,1,Depression response (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,4,10,0.0,0.0,2,11,0.0,0.0,7.059732,2.2,0.508111,9.525469,
3,1,Depression response (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,23,92,0.0,0.0,13,46,0.0,0.0,44.958575,0.884615,0.494931,1.581117,
3,1,Depression response (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,15,54,0.0,0.0,19,54,0.0,0.0,47.981693,0.789474,0.44999,1.385073,
3,1,Depression response (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,7,10,0.0,0.0,3,11,0.0,0.0,9.138933,2.566667,0.901007,7.311576,
3,1,Depression response (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,40,92,0.0,0.0,16,46,0.0,0.0,40.979912,1.25,0.789738,1.978505,
3,1,Depression response (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,26,54,0.0,0.0,24,54,0.0,0.0,49.881155,1.083333,0.721217,1.627264,
3,1,Depression response (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,8,10,0.0,0.0,4,11,0.0,0.0,11.302112,2.2,0.948872,5.100792,
3,1,Depression response (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,51,92,0.0,0.0,18,46,0.0,0.0,40.303625,1.416667,0.94553,2.122561,
3,1,Depression response (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,30,54,0.0,0.0,27,54,0.0,0.0,48.394263,1.111111,0.776873,1.58915,
3,1,Depression response (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,8,10,0.0,0.0,4,11,0.0,0.0,11.844045,2.2,0.948872,5.100792,
3,1,Depression response (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,57,92,0.0,0.0,28,46,0.0,0.0,47.896977,1.017857,0.768015,1.348975,
3,1,Depression response (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,34,54,0.0,0.0,26,54,0.0,0.0,40.258979,1.307692,0.926899,1.844925,
3,1,Depression response (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,7,10,0.0,0.0,4,11,0.0,0.0,5.412088,1.925,0.797834,4.644608,
3,1,Depression response (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,63,92,0.0,0.0,24,46,0.0,0.0,43.839441,1.3125,0.96316,1.788546,
3,1,Depression response (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,38,54,0.0,0.0,31,54,0.0,0.0,50.748471,1.225806,0.9194,1.634329,
3,1,Depression response (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,8,10,0.0,0.0,3,11,0.0,0.0,7.325201,2.933333,1.064581,8.082467,
3,1,Depression response (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,62,92,0.0,0.0,24,46,0.0,0.0,43.5272,1.291667,0.946371,1.762949,
3,1,Depression response (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,38,54,0.0,0.0,33,54,0.0,0.0,49.147599,1.151515,0.8753,1.514895,
3,1,Depression response (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,8,10,0.0,0.0,2,11,0.0,0.0,8.366515,4.4,1.209577,16.005591,
3,1,Depression response (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,48,92,0.0,0.0,21,46,0.0,0.0,44.176464,1.142857,0.788567,1.656323,
3,1,Depression response (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,34,54,0.0,0.0,27,54,0.0,0.0,47.457021,1.259259,0.899778,1.762362,
3,1,Depression response (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.5341173890460648,0.0,0.0,7,10,0.0,0.0,3,11,0.0,0.28528138528138525,15.903437,2.566667,0.901007,7.311576,
3,1,Depression response (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.16650107779415904,0.0,0.0,61,92,0.0,0.0,22,46,0.0,0.027722608906616604,40.127171,1.386364,0.991576,1.938333,
3,1,Depression response (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.12062447740929098,0.0,0.0,36,54,0.0,0.0,42,54,0.0,0.01455026455026455,43.969391,0.857143,0.676671,1.085748,
3,2,Depression remission (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,1.5787413475374117,0.0,0.0,0,10,0.0,0.0,0,11,0.0,2.492424242424242,,,,,
3,2,Depression remission (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,1,54,0.0,0.0,1,54,0.0,0.0,100.0,1.0,0.064183,15.580542,
3,2,Depression remission (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,1.5787413475374117,0.0,0.0,1,10,0.0,0.0,0,11,0.0,2.492424242424242,24.885435,3.272727,0.14828,72.233205,
3,2,Depression remission (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,2,54,0.0,0.0,4,54,0.0,0.0,75.114565,0.5,0.095552,2.616376,
3,2,Depression remission (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,1.1441551070947107,0.0,0.0,2,10,0.0,0.0,0,11,0.0,1.309090909090909,25.937599,5.454545,0.29299,101.546242,
3,2,Depression remission (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,0,92,0.0,0.0,2,46,0.0,0.0,24.987188,0.101075,0.004952,2.062965,
3,2,Depression remission (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,6,54,0.0,0.0,3,54,0.0,0.0,49.075213,2.0,0.527061,7.589257,
3,2,Depression remission (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.8015137194235931,0.0,0.0,3,10,0.0,0.0,0,11,0.0,0.6424242424242423,14.945467,7.636364,0.442602,131.752673,
3,2,Depression remission (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,2,92,0.0,0.0,2,46,0.0,0.0,28.680295,0.5,0.072738,3.43699,
3,2,Depression remission (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,7,54,0.0,0.0,4,54,0.0,0.0,56.374238,1.75,0.543614,5.633592,
3,2,Depression remission (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.5559594491425693,0.0,0.0,6,10,0.0,0.0,1,11,0.0,0.3090909090909091,13.976321,6.6,0.952189,45.747207,
3,2,Depression remission (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,13,92,0.0,0.0,3,46,0.0,0.0,29.270264,2.166667,0.649685,7.225724,
3,2,Depression remission (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,15,54,0.0,0.0,12,54,0.0,0.0,56.753415,1.25,0.646877,2.415453,
3,2,Depression remission (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.5090097337879788,0.0,0.0,5,10,0.0,0.0,1,11,0.0,0.25909090909090904,6.044247,5.5,0.767893,39.393501,
3,2,Depression remission (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,18,92,0.0,0.0,6,46,0.0,0.0,32.166455,1.5,0.638908,3.521631,
3,2,Depression remission (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,17,54,0.0,0.0,13,54,0.0,0.0,61.789298,1.307692,0.706439,2.420676,
3,2,Depression remission (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.44938630591958617,0.0,0.0,7,10,0.0,0.0,2,11,0.0,0.2019480519480519,11.024695,3.85,1.030915,14.378007,
3,2,Depression remission (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,19,92,0.0,0.0,7,46,0.0,0.0,30.590548,1.357143,0.61531,2.993346,
3,2,Depression remission (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,22,54,0.0,0.0,13,54,0.0,0.0,58.384757,1.692308,0.95459,3.000142,
3,2,Depression remission (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.44938630591958617,0.0,0.0,7,10,0.0,0.0,1,11,0.0,0.2019480519480519,8.677645,7.7,1.137606,52.118218,
3,2,Depression remission (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,31,92,0.0,0.0,7,46,0.0,0.0,35.422286,2.214286,1.056586,4.640476,
3,2,Depression remission (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.2126523629755663,0.0,0.0,30,54,0.0,0.0,20,54,0.0,0.045221027479092,55.90007,1.5,0.983879,2.286866,
3,2,Depression remission (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.5341173890460648,0.0,0.0,7,10,0.0,0.0,2,11,0.0,0.28528138528138525,7.602903,3.85,1.030915,14.378007,
3,2,Depression remission (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.3545767021127579,0.0,0.0,31,92,0.0,0.0,8,46,0.0,0.12572463768115943,27.566261,1.9375,0.969882,3.870477,
3,2,Depression remission (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,29,54,0.0,0.0,18,54,0.0,0.0,64.830836,1.611111,1.026034,2.529817,
3,2,Depression remission (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.6722708174151634,0.0,0.0,7,10,0.0,0.0,0,11,0.0,0.4519480519480519,8.959916,16.363636,1.053111,254.264415,
3,2,Depression remission (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,20,92,0.0,0.0,13,46,0.0,0.0,43.708141,0.769231,0.421354,1.40432,
3,2,Depression remission (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,28,54,0.0,0.0,17,54,0.0,0.0,47.331943,1.647059,1.02943,2.635248,
3,2,Depression remission (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.5341173890460648,0.0,0.0,7,10,0.0,0.0,2,11,0.0,0.28528138528138525,18.014955,3.85,1.030915,14.378007,
3,2,Depression remission (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.2739630673436226,0.0,0.0,31,92,0.0,0.0,13,46,0.0,0.07505576226832629,38.435902,1.192308,0.69318,2.050834,
3,2,Depression remission (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.1739274206157614,0.0,0.0,23,54,0.0,0.0,32,54,0.0,0.03025074764205199,43.549142,0.71875,0.491274,1.051555,
3,3,Adverse events (mother),Any adverse event,1,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.4290581651605166,0.0,0.0,4,10,0.0,0.0,8,11,0.0,0.1840909090909091,9.931727,0.55,0.237218,1.275198,
3,3,Adverse events (mother),Any adverse event,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.18899579409633646,0.0,0.0,41,92,0.0,0.0,22,46,0.0,0.03571941018610481,49.101303,0.931818,0.638378,1.360143,
3,3,Adverse events (mother),Any adverse event,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.21042866634526358,0.0,0.0,25,54,0.0,0.0,24,54,0.0,0.044280223619846265,40.96697,1.041667,0.688504,1.575982,
3,3,Adverse events (mother),Severe adverse event,2,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,1.5763402186230246,0.0,0.0,0,10,0.0,0.0,1,11,0.0,2.484848484848485,27.399481,0.363636,0.016476,8.025912,
3,3,Adverse events (mother),Severe adverse event,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,1.626132419977952,0.0,0.0,1,92,0.0,0.0,0,46,0.0,2.6443066473033507,25.920505,1.516129,0.062966,36.506448,
3,3,Adverse events (mother),Severe adverse event,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,1.209385611355278,0.0,0.0,2,54,0.0,0.0,1,54,0.0,1.4626135569531795,46.680014,2.0,0.186843,21.408382,
3,3,Adverse events (mother),Serious adverse event,3,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,0,10,0.0,0.0,0,11,0.0,0.0,,,,,
3,3,Adverse events (mother),Serious adverse event,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,1.6227096800621332,0.0,0.0,1,92,0.0,0.0,0,46,0.0,2.6331867057673506,49.958838,1.516129,0.062966,36.506448,
3,3,Adverse events (mother),Serious adverse event,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,1.6217170930733664,0.0,0.0,1,54,0.0,0.0,0,54,0.0,2.62996632996633,50.041162,3.0,0.124918,72.0473,
3,4,Depression severity according to HAMD (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-2.2,2.3,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,4.234277,-2.2,-6.707917,2.307917,
3,4,Depression severity according to HAMD (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.1,1.0,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.0,22.399326,0.1,-1.859964,2.059964,Brexanolone dose 60 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.2,0.9,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.81,27.653488,0.2,-1.563968,1.963968,Brexanolone dose 90 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),2 hours post-infusion,1,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-0.6,0.7,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,45.712909,-0.6,-1.971975,0.771975,
3,4,Depression severity according to HAMD (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-3.5,2.9,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,4.335898,-3.5,-9.183896,2.183896,
3,4,Depression severity according to HAMD (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-2.1,1.2,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.44,25.32285,-2.1,-4.451957,0.251957,Brexanolone dose 60 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-0.3,1.2,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.44,25.32285,-0.3,-2.651957,2.051957,Brexanolone dose 90 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),4 hours post-infusion,2,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-0.8,0.9,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,45.018401,-0.8,-2.563968,0.963968,
3,4,Depression severity according to HAMD (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-4.6,3.1,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,4.549015,-4.6,-10.675888,1.475888,
3,4,Depression severity according to HAMD (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-2.0,1.3,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.44,25.867476,-2.0,-4.547953,0.547953,Brexanolone dose 60 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-0.4,1.3,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.44,25.867476,-0.4,-2.947953,2.147953,Brexanolone dose 90 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),8 hours post-infusion,3,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-1.0,1.0,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,43.716034,-1.0,-2.959964,0.959964,
3,4,Depression severity according to HAMD (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-6.0,3.7,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,4.015598,-6.0,-13.251867,1.251867,
3,4,Depression severity according to HAMD (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-1.3,1.4,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.9599999999999997,25.430036,-1.3,-4.04395,1.44395,Brexanolone dose 60 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.7,1.4,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.9599999999999997,25.430036,0.7,-2.04395,3.44395,Brexanolone dose 90 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),12 hours post-infusion,4,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-1.1,1.0,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.0,45.124329,-1.1,-3.059964,0.859964,
3,4,Depression severity according to HAMD (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-11.3,3.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,10.940415,-11.3,-18.35587,-4.24413,
3,4,Depression severity according to HAMD (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-4.3,1.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,27.456043,-4.3,-7.435942,-1.164058,Brexanolone dose 60 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-2.3,1.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,27.456043,-2.3,-5.435942,0.835942,Brexanolone dose 90 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),24 hours post-infusion,5,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-1.6,1.1,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,34.147499,-1.6,-3.75596,0.55596,
3,4,Depression severity according to HAMD (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-12.0,4.0,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,10.370319,-12.0,-19.839856,-4.160144,
3,4,Depression severity according to HAMD (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-5.1,1.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,27.962166,-5.1,-8.235942,-1.964058,Brexanolone dose 60 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-1.4,1.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,27.962166,-1.4,-4.535942,1.735942,Brexanolone dose 90 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),36 hours post-infusion,6,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-1.9,1.1,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,33.705348,-1.9,-4.05596,0.25596,
3,4,Depression severity according to HAMD (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-12.7,4.0,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,9.224866,-12.7,-20.539856,-4.860144,
3,4,Depression severity according to HAMD (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-4.5,1.7,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,27.646083,-4.5,-7.831939,-1.168061,Brexanolone dose 60 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-3.3,1.7,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,27.646083,-3.3,-6.631939,0.031939,Brexanolone dose 90 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),48 hours post-infusion,7,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-2.4,1.2,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,35.482969,-2.4,-4.751957,-0.048043,
3,4,Depression severity according to HAMD (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-12.2,4.1,0.0,0.0,0,0,0.0,0.0,0,0,0.0,16.81,8.231301,-12.2,-20.235852,-4.164148,
3,4,Depression severity according to HAMD (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-5.5,1.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,2.5600000000000005,27.44831,-5.5,-8.635942,-2.364058,Brexanolone dose 60 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-3.7,1.6,0.0,0.0,0,0,0.0,0.0,0,0,0.0,2.5600000000000005,27.44831,-3.7,-6.835942,-0.564058,Brexanolone dose 90 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),60 hours post-infusion,8,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-2.5,1.0,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,36.87208,-2.5,-4.459964,-0.540036,
3,4,Depression severity according to HAMD (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-12.7,4.3,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,6.872137,-12.7,-21.127845,-4.272155,
3,4,Depression severity according to HAMD (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-5.0,1.7,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,26.928336,-5.0,-8.331939,-1.668061,Brexanolone dose 60 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-2.5,1.7,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,26.928336,-2.5,-5.831939,0.831939,Brexanolone dose 90 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),72 hours post-infusion,9,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-3.5,1.1,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,39.27119,-3.5,-5.65596,-1.34404,
3,4,Depression severity according to HAMD (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-12.9,3.9,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,11.369997,-12.9,-20.54386,-5.25614,
3,4,Depression severity according to HAMD (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-4.1,1.8,0.0,0.0,0,0,0.0,0.0,0,0,0.0,3.24,27.842025,-4.1,-7.627935,-0.572065,Brexanolone dose 60 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-1.6,1.8,0.0,0.0,0,0,0.0,0.0,0,0,0.0,3.24,27.842025,-1.6,-5.127935,1.927935,Brexanolone dose 90 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),7 days post-infusion,10,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,-3.2,1.4,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,32.945954,-3.2,-5.94395,-0.45605,
3,4,Depression severity according to HAMD (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Kanes 2017,2017,-11.9,4.1,0.0,0.0,0,0,0.0,0.0,0,0,0.0,0.0,15.350735,-11.9,-19.935852,-3.864148,
3,4,Depression severity according to HAMD (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-5.6,1.9,0.0,0.0,0,0,0.0,0.0,0,0,0.0,3.61,27.08675,-5.6,-9.323932,-1.876068,Brexanolone dose 60 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,-3.8,1.9,0.0,0.0,0,0,0.0,0.0,0,0,0.0,3.61,27.08675,-3.8,-7.523932,-0.076068,Brexanolone dose 90 ug/kg/hour
3,4,Depression severity according to HAMD (early phase),30 days post-infusion,11,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.5,1.3,0.0,0.0,0,0,0.0,0.0,0,0,0.0,1.6900000000000002,30.475764,0.5,-2.047953,3.047953,
3,5,Treatment acceptability (measured by dropouts),,,SUBGROUP_AND_OVERALL,Kanes 2017,2017,0.0,0.0,0.0,0.0,1,10,0.0,0.0,0,11,0.0,0.0,6.962061,3.272727,0.14828,72.233205,
3,5,Treatment acceptability (measured by dropouts),,,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 1,2018,0.0,0.0,0.0,0.0,21,92,0.0,0.0,4,46,0.0,0.0,65.478231,2.625,0.957057,7.199804,
3,5,Treatment acceptability (measured by dropouts),,,SUBGROUP_AND_OVERALL,Meltzer-Brody 2018 Study 2,2018,0.0,0.0,0.0,0.0,6,54,0.0,0.0,2,54,0.0,0.0,27.559708,3.0,0.633431,14.208326,
